eligibility_summary
Eligibility: Adults 18–70 with recurrent GBM post-STUPP, measurable/evaluable by RANO, EGFRvIII+ (IHC), adequate venous blood for collection, KPS≥70, life expectancy ≥3 mo, informed consent. Key exclusions: post-recurrence RT, recent immunosuppression/live vaccine/other chemo, unresolved AEs, prior targeted/cell/gene/immunotherapy, transplant, no MRI, major lab/viral/HIV/LVEF<50% issues, acute infection, serious cardiac/oxygen-dependent lung disease, other malignancy, TB, allergies, psych/drug abuse, pregnancy/inadequate contraception, recent trials, PI discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: EGFRvIII CAR-T (DCTY0801), an autologous, genetically engineered T‑cell therapy delivered locally to the CNS via an Ommaya reservoir, early-phase, single-arm dose escalation/expansion in recurrent glioblastoma. Mechanism of action: patient T cells are modified to express a chimeric antigen receptor that specifically recognizes the tumor-specific EGFRvIII mutant epitope on GBM cells, triggering T‑cell activation, cytokine release, and cytotoxic killing independent of HLA. Targets: EGFRvIII‑positive glioblastoma cells, by eliminating these cells, the therapy aims to disrupt EGFRvIII‑driven oncogenic signaling (e.g., PI3K/AKT and RAS/MAPK pathways).